Insider · CIK 0001510445
Douglas W Calder
Files at ZVRA (ZEVRA THERAPEUTICS, INC.), LNAI (RENOVARO INC.). First filing -, latest -.
In brief
Douglas W Calder files SEC Form 4 as director at ZVRA (ZEVRA THERAPEUTICS, INC.), and also at LNAI (RENOVARO INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Douglas W Calder has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2026 |
| May 29, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | May 30, 2025 |
| Nov 4, 2024 | LNAI RENOVARO INC. | AGrant or award Option to purchase shares of common stockderivative | +120,968 | $0.00 | $0 | 120,968 | Nov 6, 2024 |
Questions about Douglas W Calder
Answered from the filings on this page, as of the latest one.
Is Douglas W Calder buying or selling?
Douglas W Calder has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Douglas W Calder's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas W Calder has 0.
Where does Douglas W Calder file Form 4?
Douglas W Calder has filed Form 4 at ZVRA (ZEVRA THERAPEUTICS, INC.); LNAI (RENOVARO INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.